MT2025-24: A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- confirmed locally advanced or metastatic cancer including breast cancer, ovarian cancer, endometrial carcinoma, gastric/GEJ cancer, head & neck cancer, non small cell lung cancer, or colorectal cancer - women & men of childbearing age must use highly effective birth control - may not be able to do physically strenuous activity but walking and able to carry out work of a light or sedentary nature, e.g., light house work, office work - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- women who are pregnant or breastfeeding - other cancer in the past two years - significant cardiac (cardiac arrhythmias, myocardial infarction, unstable angina or congestive heart failure) or neurological disease (stroke, epilepsy, CNS vasculitis, or neurodegenerative disease) - active central nervous system (CNS) involvement - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Interventions:
Drug: Cetuximab, Drug: FT836, Drug: Paclitaxel, Drug: Trastuzumab
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC)

More Information

Description: This study is for people who have been diagnosed with advanced cancer that has not has not responded to standard treatment. FT836 is a type of cell product made up of “T cells” which are part of the immune system and are important in helping fight infections. T cells are also important in eliminating cancer cells. We want to test the safety of FT836 at different doses, to understand how the body processes and responds to FT836, and to find out what effects FT836 may have on participants and the cancer. The study will also find out what effects FT836, when given alone and with or without chemotherapy treatment (paclitaxel) and/or a monoclonal antibody (cetuximab or trastuzumab.
Study Contact: Manish Patel - patel069@umn.edu
Principal Investigator: Manish Patel
Phase: PHASE1
IRB Number: STUDY00025723